COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04332549
Recruitment Status : Withdrawn (After meeting with the FDA, SPARC concludes a BE study will not be required)
First Posted : April 2, 2020
Last Update Posted : June 1, 2020
Information provided by (Responsible Party):
Sun Pharma Advanced Research Company Limited

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : January 28, 2021
Estimated Study Completion Date : January 28, 2021